UMEC DPI — Competitive Intelligence Brief

UMEC DPI (UMEC DPI) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Long-acting muscarinic antagonist (LAMA). Area: Respiratory / Pulmonology.

marketed Long-acting muscarinic antagonist (LAMA) Muscarinic M3 receptor Respiratory / Pulmonology Small molecule

Target snapshot

UMEC DPI (UMEC DPI) — GlaxoSmithKline. UMEC (umeclidinium) is a long-acting muscarinic antagonist that blocks M3 receptors in airway smooth muscle to produce bronchodilation.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
UMEC DPI TARGET	UMEC DPI	GlaxoSmithKline	marketed	Long-acting muscarinic antagonist (LAMA)	Muscarinic M3 receptor
FF/UMEC/VI	FF/UMEC/VI	Dr. Grace Parraga	marketed	Triple combination inhaler (ICS/LAMA/LABA)	Beta-2 adrenergic receptor, muscarinic M3 receptor, glucocorticoid receptor
Budesonide/Glycopyrronium/Formoterol Fumarate	Budesonide/Glycopyrronium/Formoterol Fumarate	AstraZeneca	marketed	Inhaled corticosteroid/long-acting beta-2 agonist/long-acting muscarinic antagonist (ICS/LABA/LAMA)	Glucocorticoid receptor (budesonide); beta-2 adrenergic receptor (formoterol); muscarinic M3 receptor (glycopyrronium)
umeclidinium 62.5 µg and vilanterol 25 µg	umeclidinium 62.5 µg and vilanterol 25 µg	University of Tennessee Graduate School of Medicine	marketed	Long-acting anticholinergic and long-acting beta-2 agonist combination (LAMA/LABA)	Muscarinic M3 receptor (umeclidinium); Beta-2 adrenergic receptor (vilanterol)
Aclidinium bromide/formoterol fumarate combination	Aclidinium bromide/formoterol fumarate combination	AstraZeneca	marketed	Long-acting anticholinergic/long-acting beta-2 agonist combination (LAMA/LABA)	Muscarinic M3 receptor and beta-2 adrenergic receptor
Budesonide/formoterol and tiotropium	Budesonide/formoterol and tiotropium	Brian J Lipworth	marketed	Combination inhaled corticosteroid/long-acting beta-2 agonist/long-acting muscarinic antagonist	Glucocorticoid receptor, beta-2 adrenergic receptor, muscarinic M3 receptor
TIO	TIO	GlaxoSmithKline	marketed	Long-acting muscarinic antagonist (LAMA)	Muscarinic M3 receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Long-acting muscarinic antagonist (LAMA) class)

1. GlaxoSmithKline · 9 drugs in this class
2. AstraZeneca · 3 drugs in this class
3. Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · 1 drug in this class
4. Chiesi Farmaceutici S.p.A. · 1 drug in this class
5. IRCCS Azienda Ospedaliero-Universitaria di Bologna · 1 drug in this class
6. Lupin, Inc. · 1 drug in this class
7. Sanofi · 1 drug in this class